Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine | MicrobiomeTrials← Back to trialsNCT04880785
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-07-28Est. Completion: 2023-06-12
Enrollment target: 167 participants Locations- H. de Elche, Alicante, Alicante, Spain
- H. General de Alicante, Alicante, Alicante, Spain
- H. Bellvitge, Barcelona, Barcelona, Spain
- H. Clinic, Barcelona, Barcelona, Spain
- H. del Mar, Barcelona, Barcelona, Spain
- CHUAC, A Coruña, Coruña, Spain
- H. de Donosti, Donostia / San Sebastian, Donostia, Spain
- H. Fundación Jimenez Díaz, Madrid, Madrid, Spain
- H. Infanta Leonor, Madrid, Madrid, Spain
- H. La Princesa, Madrid, Madrid, Spain
- H. Príncipe de Asturias, Madrid, Madrid, Spain
- H. Severo Ochoa, Madrid, Madrid, Spain
- Hospital 12 de Octubre, Madrid, Madrid, Spain
- Hospital General Univ. Gregorio Marañón, Madrid, Madrid, Spain
- Hospital Univ. La Paz, Madrid, Madrid, Spain
- H. Virgen de la Victoria, Málaga, Málaga, Spain
- H. Álvaro Cunqueiro, Vigo, Pontevedra, Spain
Other microbiome trials you might be interested in
HivOpioid Use
The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in th…
New Haven, United StatesEst. completion Dec 2028
Mother-to-child HIV Transmission
The study design includes an observational prospective cohort of HIV-positive pregnant/postpartum women and their infant…
Kigali, RwandaCompleted May 2016
Cryptococcal Pneumonia
Pulmonary Cryptococcosis
Cryptococcal Meningitis
Cryptococcosis
The protocol will be carried out in accordance with International Council for Harmonisation of Technical Requirements fo…